Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd PharmaphorumBoehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.RespiratoryRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK. Respiratory Read full story Post navigation Previous: FDA Warning Letter Hits Sanofi’s Genzyme Ireland SiteNext: NICE aims to cut funding for Amgen lung cancer drug Lumykras Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
